Azathioprine for the treatment of early Parkinson's disease (AZA-PD): a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

Authors

Julia C Greenland, Kerry Dresser, Emma Cutting, Rachel Donegan, Simon Bond, Sarah J Crisp, Kirsten M Scott, Zanna J Voysey, Jonathan Holbrook, Lakmini Kahanawita, Reiss Pal, Marta Camacho, Alexander R D Peattie, Lennart R B Spindler, Young T Hong, Tim D Fryer, Caroline H Williams-Gray

Abstract

The immune system is implicated in Parkinson's disease aetiology and prognosis. Although there are effective symptomatic treatments for Parkinson's disease, there are currently no therapies that slow down disease progression. We aimed to investigate the clinical efficacy of the broadly acting peripheral immunosuppressant drug azathioprine for patients with early Parkinson's disease.

PMID:41389828 | DOI:S1474-4422(25)00386-2

UK DRI Authors

Dr Reiss Pal

Postdoctoral Researcher

Dr Reiss Pal